(Q48905216)

English

Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.

scientific article published on 19 December 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. (English)

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

magnetic resonance imaging

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

Annette Kopp-Schneider

8

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

Ali Afshar-Oromieh

object named as

A Afshar-Oromieh

1

0 references

Boris Hadaschik

object named as

B A Hadaschik

7

0 references

author name string

U Haberkorn

2

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

H P Schlemmer

3

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

M Fenchel

4

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

M Eder

5

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

M Eisenhut

6

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

M Röthke

9

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

publication date

19 December 2013

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

41

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

5

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

887-897

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

https://scigraph.springernature.com/pub.10.1007/s00259-013-2660-z

0 references

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

PSMA as a target for radiolabelled small molecules

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

Introducing parametric fusion PET/MRI of primary prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

Improved detection of localized prostate cancer using co-registered MRI and 11C-acetate PET/CT.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

Sensitivity of PET/MRI to detect recurrence of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2660-Z

21 January 2018

Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24352789

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

¹⁸F-Fluorocholine integrated PET/MRI for the initial staging of prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24352789

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-013-2660-Z

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/24352789

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48905216&oldid=1521461946"